IRADIMED CORP (NASDAQ:IRMD) reported second quarter results on Friday that landed roughly in line with revenue expectations while delivering a modest earnings per share surprise, and the stock was pointing higher in premarket trading as investors weighed the outlook for the rest of the year. The Orlando-based maker of MRI-compatible medical devices posted revenue of $20.5 million, essentially flat year over year and slightly below the consensus estimate of $20.8 million, while non-GAAP diluted EPS came in at $0.46, ahead of the $0.43 analysts had modeled.
Quarterly results in focus
The headline numbers for the three months ended June 30 show a business still in the early phase of a product transition, with the launch of the next-generation 3870 MR IV pump beginning to absorb manufacturing and operational attention. The revenue shortfall relative to expectations was less than 1.5%, so it is best characterized as inline rather than a miss. Earnings, by contrast, were supported by disciplined expense management and came in roughly 7% above consensus.
- Revenue: $20.5 million, up 0.5% from $20.4 million in Q2 2025
- GAAP diluted EPS: $0.41, down from $0.45
- Non-GAAP diluted EPS: $0.46, down from $0.49 but above the consensus estimate
- Gross margin: 74%, compared with 78% in the prior year quarter
The gross margin decline was expected by management, who noted that the initial 3870 production ramp carried startup inefficiencies. The company said it expects margin improvement in the second half as production volumes build.
Guidance and outlook
Management reaffirmed its full-year 2026 guidance and also provided a third quarter outlook, offering investors a clearer picture of the expected trajectory. The full-year revenue range of $91.0 million to $96.0 million brackets the current analyst consensus of roughly $93.1 million, with a midpoint that sits very close to the street view. On EPS, the company guided to non-GAAP diluted EPS of $2.09 to $2.24, putting the midpoint slightly above the analyst estimate of $2.12.
For the third quarter, the company expects revenue of $23.0 million to $24.5 million, a range that comfortably includes the $24.1 million consensus. Non-GAAP EPS guidance of $0.54 to $0.59 is ahead of the $0.53 analysts had penciled in for the period.
- Q3 revenue guidance: $23.0M to $24.5M vs. $24.1M consensus
- Q3 non-GAAP EPS guidance: $0.54 to $0.59 vs. $0.53 consensus
- Full-year revenue guidance: $91.0M to $96.0M vs. $93.1M consensus
- Full-year non-GAAP EPS guidance: $2.09 to $2.24 vs. $2.12 consensus
The guidance reaffirmation appears to be a key driver of the positive premarket reaction, since it confirms that the company sees the 3870 launch as on track despite the near-term margin drag.
Operational highlights
The press release emphasized early traction for the new pump platform and record demand in another product line. More than 70% of new pump orders during the quarter were for the quad stack configuration of four pumps on a single IV pole, which doubles the pump channel count from the prior standard. Management also noted that domestic monitor unit bookings set a record, suggesting that the installed base expansion remains healthy.
The company declared a regular quarterly cash dividend of $0.20 per share, payable on August 28 to stockholders of record as of August 14.
On the balance sheet, cash and cash equivalents stood at $59.1 million at quarter end, up from $51.2 million at the start of the year, while total liabilities remained modest at $13.2 million.
Cash flow from operations was $14.2 million for the first six months of 2026, up 18% from the same period in 2025, which management attributed to higher net income and lower cash outflows related to working capital items.
Market reaction and price action
The stock was up roughly 2.8% in premarket trading, a move that appears tied to the EPS beat and the maintained full-year outlook. The reaction is notable given that shares had drifted lower over the past month.
- Last week: +1.4%
- Last two weeks: -2.6%
- Last month: -2.9%
The premarket gain suggests that investors were focused more on the earnings quality and guidance than on the slight revenue shortfall or the temporary gross margin compression. Still, the company is in the middle of a product transition, and execution on the 3870 ramp will be the key variable for the remainder of the year.
Risks and considerations
The second quarter results highlight a few areas worth monitoring. The transition from the 3860 to the 3870 pump platform creates near-term revenue and margin volatility, and management explicitly acknowledged that production efficiencies will take time to materialize. The company also continues to rely on a limited number of core products, which concentrates risk around regulatory, supply chain, and adoption dynamics.
For investors tracking the stock, the positive guidance and strong cash generation provide a supportive backdrop, but the next few quarters will determine whether the 3870 ramp delivers the revenue acceleration embedded in the full-year targets.
Readers looking for additional historical earnings context can review the earnings information page for a longer-term view of quarterly performance. For updated estimates and projections beyond the current fiscal year, the forecast page provides a useful reference.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
IRADIMED (NASDAQ:IRMD) Beats Q2 EPS, Reaffirms Full-Year Guidance
IRADIMED CORP (NASDAQ:IRMD) reported second quarter results on Friday that landed roughly in line with revenue expectations while delivering a modest earnings per share surprise, and the stock was pointing higher in premarket trading as investors weighed the outlook for the rest of the year. The Orlando-based maker of MRI-compatible medical devices posted revenue of $20.5 million, essentially flat year over year and slightly below the consensus estimate of $20.8 million, while non-GAAP diluted EPS came in at $0.46, ahead of the $0.43 analysts had modeled.
Quarterly results in focus
The headline numbers for the three months ended June 30 show a business still in the early phase of a product transition, with the launch of the next-generation 3870 MR IV pump beginning to absorb manufacturing and operational attention. The revenue shortfall relative to expectations was less than 1.5%, so it is best characterized as inline rather than a miss. Earnings, by contrast, were supported by disciplined expense management and came in roughly 7% above consensus.
The gross margin decline was expected by management, who noted that the initial 3870 production ramp carried startup inefficiencies. The company said it expects margin improvement in the second half as production volumes build.
Guidance and outlook
Management reaffirmed its full-year 2026 guidance and also provided a third quarter outlook, offering investors a clearer picture of the expected trajectory. The full-year revenue range of $91.0 million to $96.0 million brackets the current analyst consensus of roughly $93.1 million, with a midpoint that sits very close to the street view. On EPS, the company guided to non-GAAP diluted EPS of $2.09 to $2.24, putting the midpoint slightly above the analyst estimate of $2.12.
For the third quarter, the company expects revenue of $23.0 million to $24.5 million, a range that comfortably includes the $24.1 million consensus. Non-GAAP EPS guidance of $0.54 to $0.59 is ahead of the $0.53 analysts had penciled in for the period.
The guidance reaffirmation appears to be a key driver of the positive premarket reaction, since it confirms that the company sees the 3870 launch as on track despite the near-term margin drag.
Operational highlights
The press release emphasized early traction for the new pump platform and record demand in another product line. More than 70% of new pump orders during the quarter were for the quad stack configuration of four pumps on a single IV pole, which doubles the pump channel count from the prior standard. Management also noted that domestic monitor unit bookings set a record, suggesting that the installed base expansion remains healthy.
The company declared a regular quarterly cash dividend of $0.20 per share, payable on August 28 to stockholders of record as of August 14.
On the balance sheet, cash and cash equivalents stood at $59.1 million at quarter end, up from $51.2 million at the start of the year, while total liabilities remained modest at $13.2 million.
Cash flow from operations was $14.2 million for the first six months of 2026, up 18% from the same period in 2025, which management attributed to higher net income and lower cash outflows related to working capital items.
Market reaction and price action
The stock was up roughly 2.8% in premarket trading, a move that appears tied to the EPS beat and the maintained full-year outlook. The reaction is notable given that shares had drifted lower over the past month.
The premarket gain suggests that investors were focused more on the earnings quality and guidance than on the slight revenue shortfall or the temporary gross margin compression. Still, the company is in the middle of a product transition, and execution on the 3870 ramp will be the key variable for the remainder of the year.
Risks and considerations
The second quarter results highlight a few areas worth monitoring. The transition from the 3860 to the 3870 pump platform creates near-term revenue and margin volatility, and management explicitly acknowledged that production efficiencies will take time to materialize. The company also continues to rely on a limited number of core products, which concentrates risk around regulatory, supply chain, and adoption dynamics.
For investors tracking the stock, the positive guidance and strong cash generation provide a supportive backdrop, but the next few quarters will determine whether the 3870 ramp delivers the revenue acceleration embedded in the full-year targets.
Readers looking for additional historical earnings context can review the earnings information page for a longer-term view of quarterly performance. For updated estimates and projections beyond the current fiscal year, the forecast page provides a useful reference.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »